PAP22 Antibody

Prostatic Acid Phosphatase (PAP) Antibodies

PAP is a key antigen in prostate cancer immunotherapy. Antibodies targeting PAP-derived peptides have shown therapeutic potential:

• A mutated 42mer PAP peptide (MutPAP42mer) induced robust CD8+/CD4+ T-cell responses in mice, enhancing tumor growth inhibition in prostate cancer models .

• Flow cytometry with anti-PAP antibodies (e.g., ab224802) demonstrated specificity for PAP-expressing LNCaP prostate cancer cells .

Key Features of PAP Antibodies:

PAPP-A and PAPP-A2 Antibodies

Pregnancy-associated plasma proteins (PAPP-A/PAPP-A2) are metalloproteinases with roles in cancer progression:

• mAb-PA, a neutralizing antibody against PAPP-A, reduced ovarian tumor growth and ascites in preclinical models .

• Anti-PAPP-A2 antibodies (e.g., AF1668) detect ~250 kDa bands in Western blot analyses .

Comparative Analysis of PAPP-A Antibodies:

Clinical Translation

• PAPMET2 trial: Cabozantinib (a multi-kinase inhibitor) is being tested with/without atezolizumab (anti-PD-L1) in papillary renal cell carcinoma, though no direct link to PAP22 is noted .

• Ovatar models: PAPP-A-targeting antibodies improved survival in ovarian cancer tumorgrafts, highlighting biomarker-driven therapeutic strategies .

Technical Validation

Antibodies are rigorously validated for specificity:

• Western blot: Anti-PAPP-A antibodies show bands at ~200 kDa (PAPP-A) and ~250 kDa (PAPP-A2) .

• Immunohistochemistry: Consistent staining patterns align with RNA expression data in the Human Protein Atlas .